537 Local immunotherapy with INTASYL™ self-delivering RNAi targeting CTLA-4 provides robust tumor control in vivo

Benjamin Cuiffo, Melissa Maxwell, Dingxue Yan, Brianna Rivest, Andrew Boone, Shenghua Zhou, James Cardia, Simon Fricker
2022 Regular and Young Investigator Award Abstracts   unpublished
or INTASYL 27790 at two dose concentrations were administered IT; anti-CTLA-4 monoclonal antibody (mAb; clone 9D9) was administered intraperitoneally (IP). Tumor volumes and body weights were recorded longitudinally. Results mCTLA-4-targeting INTASYL 27790 provided concentration-associated silencing of mCTLA-4 in vitro. When administered IT, mCTLA-4-targeting INTASYL 27790 elicited robust dose-associated antitumor efficacy in both in vivo tumor models compared with vehicle-or NTC-treated
more » ... comparable to that observed under systemic IP treatment with anti-CTLA4 mAb. Conclusions These data show IT INTASYL targeting mouse CTLA4 elicits robust on-target dose concentration-associated antitumor efficacy in two syngeneic tumor models in vivo and provide POC for targeting CTLA-4 IT with INTASYL. Ethics Approval Animal studies were performed at Pharma Models LLC, Marlborough, MA 01752, under standard protocol approved by their IACUC.
doi:10.1136/jitc-2022-sitc2022.0537 fatcat:3lancfhed5emjky2sr7yesjz54